Company: VEEAW
Filing Date: 2025-08-14
Form Type: 424B4
Source: 0001213900-25-076086
Chunk: 79

Company: VEEA INC.
Filing Date: 2025-08-14
Form: 424B4
Chunk 79
---
 future.

<div align='center'>41</div>

Risks Related to this Offering

Our management will have broad discretion over the use of the net proceeds from this offering, you may not agree with how we use the proceeds, and the proceeds may not be invested successfully.

Our management will have broad
discretion in the application of the net proceeds from this offering, and our stockholders will not have the opportunity as part of their
investment decision to assess whether the net proceeds are being used appropriately. Because of the number and variability of factors
that will determine our use of the net proceeds from this offering, their ultimate use may vary substantially from their currently intended
use. The failure by our management to apply these funds effectively could harm our business. See “Use of Proceeds”
on page 45 for a description of our proposed use of proceeds from this offering.

Purchasers in this offering may experience immediate and substantial dilution in net tangible book value.

The public offering price per share of common stock may be substantially
higher than the pro forma as adjusted net tangible book value per share of our common stock after giving effect to this offering. As a
result of the dilution to investors purchasing securities in this offering, investors may receive significantly less than the purchase
price paid in this offering, if anything, in the event of the liquidation of our company. See the section entitled “Dilution”
above for a more detailed discussion of the dilution you may incur if you participate in this offering. To the extent shares are issued
under outstanding options and warrants at exercise prices lower than the public offering price of our common stock in this offering, you
will incur further dilution.

Your ownership may be diluted if additional capital stock is issued to raise capital, to finance acquisitions or in connection with strategic transactions.

We will require additional,
substantial financing in order to complete our clinical trials. We intend to seek to raise additional funds for our operations, to finance
acquisitions or to develop strategic relationships by issuing equity or convertible debt securities in addition to the securities issued
in this offering, which would reduce the percentage ownership of our existing stockholders. Our board of directors has the authority,
without action or vote of the stockholders, to issue all or any part of our authorized but unissued shares of common or preferred stock.
Our articles of incorporation authorize us to issue up to 551,000,000 shares of common stock and 1,000,000 shares of preferred stock.
Future issuances of common or preferred stock would